UPPSALA, Sweden, April 27, 2011 /PRNewswire/ -- Beactica, the leading Swedish fragment-based drug discovery company, today announced that it has entered into an agreement with Janssen Research & Development, a division of Janssen Pharmaceutica NV. Under the agreement, Beactica will use its proprietary drug discovery platform, Sprint(TM), to generate small-molecule lead compounds against undisclosed targets of therapeutic interest to Janssen. Financial terms of the agreement were not disclosed.
"We are pleased to work with Janssen and look forward to utilising Beactica's platform to support the progress of one of their prioritized programmes" said Beactica CEO, Dr Per Kallblad. "Fragment-based approaches to drug discovery are creating new pathways towards small-molecule leads of high-quality and Beactica has worked hard to win a reputation for being at the cutting-edge of advances".
Janssen is the fourth global top-20 pharmaceutical company to enter into an agreement with Beactica in the past 18 months.
Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the biophysical interaction of molecules in order to generate novel therapeutics. The Company offers expertise and services in the area of surface plasmon resonance (SPR) biosensor-based small molecule interaction analysis and partnerships for fragment-based lead generation using its proprietary Sprint(TM) platform. Founded in 2006 based on research carried out at Uppsala University and first-hand experience from the drug discovery industry, Beactica has established a robust reputation as the leader in SPR-based small molecule drug discovery. As well as providing services and building collaborations with external companies, Beactica is progressing its own drug discovery programmes. The company has its headquarter in Uppsala, Sweden. For more information, please visit http://www.beactica.com.
For additional information please contact Dr Per Kallblad, Beactica CEO, +46-18-56-08-80.
SOURCE Beactica AB